secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2026-05-14T20:05:05+00:00
Accession:  0001708599-26-000036
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics Q1 2026 net loss $6.9M; Phase 1b study of SER-252 underway
------------------------------------------------------------------------------

- Net loss of $6.9M ($0.58 per share) for Q1 2026 vs. $4.8M ($0.49) in Q1 2025.
- R&D expenses $3.2M, G&A $3.1M; total operating expenses $6.3M.
- Cash and equivalents $24.5M at March 31, 2026; additional $5.2M from PIPE in April.
- SER-252 Phase 1b registrational study underway; first patient dosed Feb 2026; TFL data from SAD arm expected H1 2027.
- Closed $21.2M private placement in March/April 2026; Senior Convertible Note amended to remove further borrowing obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000036/0001708599-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000036/ser-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001708599-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer